Valiant Laboratories Receives Show Cause Notice Regarding ITC Disallowance
The potential financial implication of ₹70.81 lakhs is relatively small for the company.
The company has received a show cause notice indicating potential financial penalties.
* Valiant Laboratories received a Show Cause Notice on 29 September 2025 from the Assistant Commissioner of CGST & Central Excise, Navi Mumbai. * The notice pertains to the alleged wrong availment of Input Tax Credit (ITC) on capital goods for the period April 2021 to March 2022. * The Show Cause Notice proposes disallowance of ITC of ₹64.37 lakhs along with a penalty, aggregating to approximately ₹70.81 lakhs. * The company is currently evaluating appropriate representations regarding the matter.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under legal. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.